Plaque Psoriasis Treatment: Roflumilast Adverse Effects
Linda Stein Gold, MD, and Jennifer Soung, MD, provides an overview of the safety profile and topical vehicle of roflumilast for the treatment of plaque psoriasis.
Roflumilast Itch Response for Plaque Psoriasis Treatment
Linda Stein Gold, MD, discusses the itch response of roflumilast for the treatment for plaque psoriasis.
Plaque Psoriasis Treatment: Roflumilast Phase III Results
Experts in plaque psoriasis discuss the primary endpoint data responses of roflumilast in the DERMIS-1/DERMIS-2 trials.
Roflumilast: Plaque Psoriasis Phase III Trial Overview
Jennifer Soung, MD, provides an overview of the phase III trials, DERMIS-1/DERMIS-2, in which roflumilast was used to treat plaque psoriasis
Evidence Based Treatment Options for Plaque Psoriasis
Linda Stein Gold, MD, and Jennifer Soung, MD, provide an overview of the different, evidence-based topical strategies for treating plaque psoriasis.
Key Takeaways on the Management of Atopic Dermatitis
Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.
Ongoing Challenges in the Management of Atopic Dermatitis
Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.
Atopic Dermatitis: Practical Advice on Selecting and Using JAK Inhibitors
Concluding their focused discussion on JAK inhibitors in atopic dermatitis, panelists share advice on the optimal selection based on route of administration and use of these agents.
Recent Approval of Oral JAK Inhibitors for Atopic Dermatitis
A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.
Topical Ruxolitinib Use in Atopic Dermatitis
A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.
JAK Inhibitors in Atopic Dermatitis: Historical Use and Mechanisms of Action
Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.
Treatment for Mild to Moderate vs Moderate to Severe Atopic Dermatitis
Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.
Atopic Dermatitis Overview: Pathophysiology, Diagnosis, and Burden
Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.
Advice for Clinicians on JAK Inhibitors
Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.
Treating Atopic Dermatitis with Ruxolitinib
Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.
Risk of Systemic Absorption with JAK Inhibitors
Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.
Reviewing Clinical Trial Data for JAK Inhibitors
Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.
Safety and Efficacy of JAK Inhibitors
Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.
An Overview of JAK Inhibitors
Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.